Join
Live feed
·
PRReleasevia Quantisnow
AC Immune SA logo

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

ByQuantisnow·Wall Street's wire, on your screen.
ACIU· AC Immune SA
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACIU (AC Immune SA) and more on Quantisnow.